Curis (CRIS) Receivables - Net (2010 - 2025)
Curis' (CRIS) quarterly Receivables - Net came in at $3.2 million in Q3 2025, up 8.9% on a YoY basis from $3.0 million in Q3 2024, and up 17.84% quarter-over-quarter from $2.8 million in Q2 2025.
Analysis
Curis (CRIS) Receivables - Net (2010 - 2025) Analysis & Trends
Curis (CRIS) has reported Receivables - Net for 16 consecutive years, with $3.2 million the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Receivables - Net rose 8.9% year-over-year to $3.2 million; the trailing twelve-month figure through Sep 2025 stood at $3.2 million (up 8.9% YoY), and the FY2024 full-year result was $3.3 million, up 19.86% from the prior year.
- Receivables - Net advanced to $3.2 million in Q3 2025 per CRIS's latest filing, from $2.8 million in the prior quarter.
- Across five years, Receivables - Net topped out at $3.3 million in Q4 2024 and bottomed at $2.1 million in Q1 2022.
- Historically, Receivables - Net has averaged $2.7 million across 5 years, with a median of $2.8 million in 2025.
- The sharpest annual moves came in 2021 and 2024: Receivables - Net dropped 12.92% in 2021, then grew 19.86% in 2024.
- Over 5 years, Receivables - Net stood at $3.2 million in 2021, then fell by 7.72% to $3.0 million in 2022, then fell by 6.08% to $2.8 million in 2023, then increased by 19.86% to $3.3 million in 2024, then fell by 3.17% to $3.2 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods registered $3.2 million, $2.8 million, and $2.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Curis | 2.63 Mn | -2.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 2.75 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Sep 30, 2023 | 2.85 Mn |
| Jun 30, 2023 | 2.39 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | 2.98 Mn |
| Sep 30, 2022 | 2.89 Mn |
| Jun 30, 2022 | 2.40 Mn |
| Mar 31, 2022 | 2.06 Mn |
| Dec 31, 2021 | 3.22 Mn |
| Sep 30, 2021 | 2.96 Mn |
| Jun 30, 2021 | 2.38 Mn |
| Mar 31, 2021 | 2.18 Mn |
| Dec 31, 2020 | 3.04 Mn |